Cancer Aware · Patient & Family Guide

Causes and Risk Factors

Risk factors can help guide prevention and investigation, but they cannot explain why one particular person develops cancer. Care should focus on support, not blame.

Educational information for patients and families. This guide supports, but does not replace, individualized medical advice. It cannot diagnose, stage cancer or prescribe treatment.

All 25 chapters

Chapter 3 of 25

What you will learn

  • Understand estrogen exposure, metabolism and inherited risk.
  • Identify useful risk-reduction steps without promises.
  • Know why symptoms still matter at any body size or age.

Hormones and the endometrium

Estrogen stimulates the uterine lining to grow. Progesterone normally balances that stimulation during ovulatory cycles. Long periods of estrogen exposure without adequate progesterone can increase the likelihood of hyperplasia and some endometrioid cancers. This may occur with infrequent ovulation, including some people with polycystic ovary syndrome, or with estrogen-only menopausal therapy when a uterus is present.

Menopausal hormone treatment should be individualized. People with a uterus generally need appropriate endometrial protection when using systemic estrogen. Vaginal low-dose preparations and systemic therapy are not interchangeable; discuss the actual product and symptoms with a clinician. Do not change a prescription based only on a general risk list.

Body weight and metabolic health

Higher amounts of body fat can increase estrogen production after menopause and are associated with insulin resistance and inflammation. Obesity and diabetes are associated with endometrial cancer risk, but these are complex biological and social conditions. Cancer also occurs in people without these factors. Weight stigma can delay diagnosis and should never be part of care.

Sustainable physical activity, balanced nutrition and appropriate diabetes management support general health. If weight management is a goal, ask for respectful, evidence-based support that accounts for medicines, mobility, finances and wellbeing. No diet guarantees prevention, and rapid weight loss during cancer treatment can be harmful. Prevention advice should not postpone assessment of bleeding.

Age, reproductive history and medicines

Risk rises with age, although premenopausal cases occur. Earlier onset of periods, later menopause and fewer pregnancies can be associated with a longer lifetime of endometrial stimulation. These are population associations, not reasons to make reproductive choices out of fear. Pregnancy and combined hormonal contraceptive use are associated with lower risk, but contraceptives have their own benefits, contraindications and adverse effects.

Tamoxifen can increase the risk of endometrial changes and cancer, particularly after menopause, while offering important benefits for appropriately selected breast cancer patients. Report abnormal bleeding promptly. Do not stop tamoxifen without discussing the balance of benefits and risks with the breast oncology team. Routine ultrasound screening in an asymptomatic average-risk tamoxifen user is not a substitute for symptom-led care.

Lynch syndrome and family history

Lynch syndrome is an inherited predisposition caused by a pathogenic variant in a DNA mismatch repair gene or certain EPCAM changes. It can increase risks of endometrial, colorectal and other cancers. Tumour testing can identify people who may need genetic counselling, even without a striking family history. A mismatch repair deficient tumour does not automatically mean inherited Lynch syndrome.

Tell the team about cancers in close relatives, their ages at diagnosis and known genetic results. Genetic counselling can explain testing, implications for relatives, privacy considerations and prevention choices. For confirmed carriers, surveillance and risk-reducing surgery discussions are individualized by gene, age and reproductive plans. The evidence for screening to prevent death is more limited than the evidence supporting risk-reducing surgery after childbearing in appropriate patients.

Practical prevention and misconceptions

Helpful stepImportant limit
Assess unexpected bleeding promptlySymptoms cannot establish the diagnosis
Manage anovulation and endometrial protectionTreatment requires a clinician's assessment
Discuss family history and tumour MMR resultsA tumour result is not a germline diagnosis
Maintain sustainable activity and metabolic careHealthy habits cannot eliminate all risk

Endometrial cancer is not contagious and is not evidence of poor hygiene or sexual behaviour. HPV vaccination remains valuable for other cancers but is not established prevention for endometrial cancer. Ask which risks change your follow-up and which are simply background information.

Related chapters

References and review status

Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.

Evidence scope and update policy